Monday , 26 February 2024

Design and In-vitro Characterization of Lisinopril Retentive Floating Tablets

T. Jahnavi*, Bh. Sriswetha, D. Raghava, K. Nageswara Rao
Department of Pharmaceutical Technology, K.G.R.L College of Pharmacy, Bhimavaram-534201, Andhra Pradesh, India

A b s t r a c t
Lisinopril is a potent, competitive inhibitor of angiotensin-converting enzyme (ACE), the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Lisinopril may be used to treat hypertension and symptomatic congestive heart failure, to improve survival in certain individuals following myocardial infarction, and to prevent the progression of renal disease in hypertensive patients with diabetes mellitus and microalbuminuria or overt nephropathy. The object of the present work is preparing lisinopril gastro-retentive floating tablets. The gas-generating agent accrual was added in different concentrations with varying amounts of retardation polymers. HPMC K100M, Sodium alginate, and HPMC K200 were used as retarding polymers. The formulation blend was evaluated for various physicochemical properties and all the parameters were found to be within limits. The formulations F1-F9 were formulated and evaluated for various quality control parameters. All the formulations passed the tests and the results were within limits. From the dissolution data, it was evident that formulation F4 and F9 was found to be best with a maximum % drug release of 98.9% and 98.2% and a floating time of 12 hours.
Keywords: Lisinopril, gastro-retentive floating tablets

Scroll To Top